BioWorld

Jan. 5, 2006

View Archived Issues

After Adding $25M, Novacea To Launch DN-101 Phase III

Closing the second tranche of a Series C financing begun two years ago, Novacea Inc. raised more than $25 million - money it will use to launch a Phase III trial with DN-101 to treat advanced prostate cancer. (BioWorld Today) Read More

Alcon Signs Kalypsys For Small-Molecule Research

Read More

Defense Bill Provides Funding For Research By AVI, Others

Read More

Medicure Raising C$12M In Bought Deal Financing

Read More

Other News To Note

Read More

Appointments And Advancements

Read More